patatin like domain 4, phospholipase and triacylglycerol lipaseGenealiases: DXS1283E · GS2 · iPLA2eta
Q-omics provides the consensus-scored PNPLA4 profile across patient tissues and cancer cell-line models. PNPLA4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PNPLA4 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, PNPLA4 protein abundance shows 20,303 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where PNPLA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNPLA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNPLA4 survival associations across molecular data types. PNPLA4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNPLA4 RNA expression–survival associations across cancer types. High PNPLA4 expression shows unfavorable associations in HNSC and LGG, but favorable associations in KIRC, ACC, READ and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PNPLA4 RNA expression.
This table summarizes PNPLA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PNPLA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNPLA4 shows lower tumor expression in THCA, KIRC, KIRP, UCEC and KICH and higher tumor expression in READ. The THCA box plot shows higher PNPLA4 RNA expression in normal versus tumor tissue (log2 FC = −1.216, t-test p < 0.001).
This table shows molecular features associated with PNPLA4 in patient tissues and cancer cell lines. In patient samples, PNPLA4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNPLA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
